Overview of Tetralgin N

Tetralgin N is a pharmaceutical preparation classified as a fixed-dose combination drug that functions primarily as a combined analgesic (pain-relieving) and antipyretic (fever-reducing) agent. This medicine belongs to the broad non-opioid analgesic class and is designed for the oral route of administration, typically manufactured as a synthetic tablet. Its composite nature, which includes an active component that is a pyrazolone derivative, makes its mechanism distinct from conventional non-steroidal anti-inflammatory drugs (NSAIDs).

Quick Facts
Active Ingredients	Sodium Metamizole, Phenobarbital, Caffeine
Form	Oral Tablet
Pharmacological Class	Combined Analgesic and Antipyretic
Common Use	Relief of moderate-to-severe pain and fever
Origin	Synthetic Chemical Compounds

Composition and General Therapeutic Role

The medicine contains three distinct active ingredients: Sodium Metamizole (also known as Dipyrone or Analgin), Phenobarbital, and Caffeine. Sodium Metamizole provides the core pain and fever relief. Metamizole is characterized by a rapid onset and pronounced analgesic and antipyretic capabilities, supporting its use in acute pain management. This indicates the medicine's fundamental strength in addressing severe discomfort and hyperthermia.

The formulation's unique balance is established by the inclusion of Phenobarbital, a mild barbiturate and sedative, alongside Caffeine, a CNS stimulant. The combination is intentionally structured to ensure the components work synergistically: the Metamizole targets the central nervous system to reduce pain, while the secondary ingredients offer mild spasmolytic (cramp-relieving) action and maintain mental alertness. This combination strategy is intended to provide comprehensive relief that includes addressing pain, fever, and associated tension, such as that experienced during a severe headache or muscular aches.

What side effects are possible with Tetralgin N?

Possible Side Effects and Safety Information

The safety profile of Tetralgin N is determined by the characteristics of its three active ingredients: Sodium Metamizole, Phenobarbital, and Caffeine. Regulatory documents categorize adverse effects primarily by frequency and the organ system affected.

Serious and Rare Adverse Reactions

The most serious documented safety concern associated with the Metamizole component is agranulocytosis, a rare, life-threatening reduction in white blood cells. This reaction is considered non-dose-dependent and can occur at any time during or shortly after treatment. Other serious but rare reactions listed in official labeling include anaphylactic shock and severe skin conditions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Common and System-Specific Effects

The Phenobarbital component is associated with effects on the Nervous System, including somnolence (drowsiness) and lethargy. The Metamizole component may cause a temporary drop in blood pressure (hypotension) classified as uncommon. Adverse effects on the Gastrointestinal System, such as nausea, are also documented. Due to Metamizole, a harmless red coloration of the urine may occur, a non-clinical effect noted in regulatory materials.

Safety Considerations and Restrictions

Official prescribing information specifies that the medicine is contraindicated in patients with marked hepatic or renal impairment. The safety profile also includes the risk of physical dependence and tolerance associated with the Phenobarbital component, which increases with the duration of use. Furthermore, Phenobarbital is a known enzyme inducer, a high-level safety note regarding its potential to affect the safety profile of other co-administered medications.

Overdose and Emergency Response

The official regulatory profile for Tetralgin N overdose is defined by the combined toxicity of its active ingredients, primarily presenting as severe disturbances in the central nervous and cardiovascular systems.

Officially Documented Overdose Manifestations

Overdose may manifest with a range of symptoms reflecting both depression and stimulation, including:

CNS Depression: Lethargy, somnolence, confusion, stupor, leading potentially to coma.
Respiratory Compromise: Hypoventilation and respiratory depression.
Cardiovascular Effects: Hypotension, bradycardia, and signs of circulatory collapse.
Stimulant Effects: Paradoxical agitation, tremors, and tachycardia (rapid heart rate).

Severe Outcomes and Emergency Actions

Overdose is officially classified as life-threatening due to the risk of severe outcomes, including apnea, shock, and cardiac arrest. Population-specific notes indicate increased risk in the elderly and a potential for life-threatening toxicity in pediatric patients.

Immediate Medical Help Required: Seek immediate medical attention for any suspected overdose or the onset of severe symptoms. The medicine must be stopped immediately if signs of the severe hematological risk of agranulocytosis (such as fever, chills, or sore throat) appear, and urgent medical assistance is required.

Management: Treatment is defined as symptomatic and supportive. No specific antidote is known for the Metamizole or Caffeine components, and the use of Flumazenil is contraindicated in the context of barbiturate toxicity. Procedures may include gastric decontamination, maintenance of an adequate airway, and continuous monitoring of vital signs.

Therapeutic Uses of Tetralgin N

The primary role of Tetralgin N is to provide short-term, supportive symptomatic relief in clinical settings marked by heightened patient distress. The core ingredient in the combination is commonly used for managing symptoms related to physical discomfort and systemic imbalance. This preparation is relevant across domains where additional symptomatic support is needed, primarily in conditions associated with acute or disruptive episodes.

Comprehensive Symptom Management

This combination is used for managing symptom clusters that may become intense or disruptive, particularly in episodes of symptoms related to physical discomfort such as headache, toothache, neuralgia, myalgia, and arthralgia. It also is applied in addressing symptom clusters of symptoms related to systemic imbalance linked to infectious-inflammatory sicknesses and symptoms of increased muscular activity in conditions like dysmenorrhea (menstrual pain) or colic. This dual therapeutic action provides support that helps ease the symptom burden and supports general well-being during symptomatic phases.

“It is relevant when symptomatic relief is needed for pain that includes a strong cramping or tension component.”

Quick Fact: Relief for Combined Symptoms

Quick Fact: Relief for Combined Symptoms
Therapeutic Domains	Pain Relief, Fever Reduction, Cramp Relief
Severity Relevance	Symptoms that interfere with daily functioning, acute states
Key Scenarios	Acute pain, fever, spastic episodes
Patient Benefit	Assists with maintaining functional stability

Eligibility and Restrictions for Use

Eligibility and Contraindications

Tetralgin N is contraindicated for several specific populations based on official regulatory labeling. This includes individuals with known hypersensitivity to Metamizole, other pyrazolones, or barbiturates. Patients with impaired bone marrow function or a history of drug-induced agranulocytosis must not use this medicine. Use is also prohibited in patients with severe hepatic or renal impairment, severe respiratory depression, and those with Acute Intermittent Porphyria.

Use is contraindicated during the third trimester of pregnancy and is generally not advisable while breastfeeding, as active ingredients are excreted in breast milk. The medicine is contraindicated for infants below three months or five kilograms.

Restricted and Conditional Use

Use is officially permitted for adults and adolescents from 15 years of age or older for standard labeled conditions. However, the fixed-dose tablet is not recommended for children younger than 15 years of age. Use requires caution and often a reduced dosage in the elderly, debilitated patients, and those with non-severe liver or kidney impairment. Patients with a history of drug abuse or alcoholism also require particular care due to the dependence risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This medicine, a combination of Metamizole, Phenobarbital, and Caffeine, has officially documented interaction patterns primarily driven by drug-metabolizing enzyme activity.

Pharmacokinetic Interactions and Restrictions

The Phenobarbital component is a potent inducer of major liver enzymes, including CYP3A4, CYP2C9, and CYP2C19, as well as the transporter P-glycoprotein. This induction accelerates the metabolism of many co-administered substances, resulting in reduced plasma concentration and potential therapeutic failure. This effect mandates that Oral Contraceptives require the use of an additional non-hormonal barrier method to prevent reduced efficacy. The Metamizole component also induces CYP2B6 and CYP3A4, further contributing to lowered systemic exposure of drugs like Ciclosporin and Bupropion.

Due to this metabolic acceleration, co-administration with critical P-gp and CYP substrates, such as certain antiretrovirals and the antifungal Voriconazole, is formally contraindicated in regulatory documents.

Pharmacodynamic and Consumption Interactions

The combination of active ingredients presents an official risk of enhanced sedation when taken with alcohol or other CNS depressants (including opioids and benzodiazepines). Additionally, a pharmacodynamic interaction exists with Methotrexate, where the co-administration increases the documented risk of hematotoxicity. Interaction severity is also noted to be increased in populations with hepatic or renal impairment due to reduced clearance of the active components.

Mechanism of Action

Tetralgin N is a combination analgesic whose effects stem from the distinct mechanisms of its multiple active components, which collectively influence several signaling pathways, resulting in modulation of heightened physiological activity.

Modulates Prostaglandin Synthesis and Release

This domain involves inhibiting cyclooxygenase (COX) enzymes, particularly in the central nervous system, to suppress the formation of prostaglandins. This modification of early molecular steps in inflammatory and pain signaling cascades decreases the quantity of specific mediators, leading to downstream alterations in central temperature and nociceptive signaling.

Engages Opioid Receptor-Mediated Signaling

This mechanism acts as an agonist at opioid receptors (e.g., mu-opioid receptors) in the brain and spinal cord, modulating the release of neurotransmitters. Initiating these signaling sequences modulates endogenous inhibitory pathways, contributing to a reduction in nociceptive transmission.

Adjusts Neural Excitability and GABAergic Activity

This domain involves components that interact with GABA receptors or affect neuronal voltage-gated channels. By engaging mechanisms that influence feedback regulation within neural pathways, the drug modifies the excitability of target neurons, resulting in attenuation of downstream neurophysiological activity.

Supports Pathway Activity via Adenosine Receptor Antagonism

This mechanism involves modulating pathways associated with wakefulness and vascular tone, primarily by acting as an adenosine receptor antagonist. This activity influences the activity of specific signaling pathways in the central nervous system, modifying downstream mediator activity.

Dosage and Administration Information

How to Use Tetralgin N

Tetralgin N is a fixed-combination medication that must be used strictly according to a healthcare professional's prescription. The composition of Tetralgin products can vary by country, but generally includes a combination of analgesic, antipyretic, and sedative agents such as metamizole (or analgin), codeine, caffeine, and phenobarbital. Due to the presence of an opioid (codeine) and a barbiturate (phenobarbital or a related compound like butalbital in some similar formulations), there is a risk of addiction, abuse, and misuse.

General Administration

Oral Use: Tetralgin N tablets or capsules are typically taken by mouth. They should be swallowed whole with water. Do not crush, chew, or dissolve the dose unless explicitly instructed by your physician.
Timing: The medication is generally taken as needed for pain relief. For optimal effect, it is often recommended to take it as soon as a headache or pain begins.
Duration of Use: Do not use this medication for an extended period. Prolonged or repeated use may lead to physical dependence and should be avoided.

Dosage Information (General Adult Guidance)

Component	Dose per Capsule/Tablet (Example)	Frequency	Maximum Daily Dose (Example)
Combination	1 to 2 units	Every 4 hours, as needed	Not to exceed 6 units

Note: This is a generalized dosing schedule for similar fixed-dose opioid/barbiturate combinations and may not reflect the specific Tetralgin N formulation you possess. The prescribed dose and frequency may vary based on the specific formulation, the severity of the pain, and individual patient factors. Never exceed the dose or frequency recommended by your prescribing physician or as detailed in the official Patient Information Leaflet.

Important Safety Precautions

Do not abruptly discontinue use if you have been taking the medication regularly; your dose should be gradually tapered by a doctor to prevent potential withdrawal symptoms.
Avoid consuming alcohol or other central nervous system depressants while taking Tetralgin N, as this can increase the risk of severe side effects, including respiratory depression.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tetralgin N

Evidence for use in Acute Pain Management

The research on the Metamizole component of Tetralgin N was studied for outcomes related to physical discomfort, such as acute pain following dental procedures or musculoskeletal discomfort. The evidence base primarily involves Randomized Controlled Trials (RCTs) and Systematic Reviews focusing on the core analgesic component. These studies explored how symptoms change over time shortly after administration, tracking pain intensity scores and measuring time intervals related to symptom observation in primarily adult populations.

However, the specific evidence from dedicated trials on the triple-drug combination (Metamizole, Phenobarbital, and Caffeine) is limited. Comparative evidence that fully isolates the contribution of each ingredient is lacking, meaning the research relies largely on the established data for Metamizole alone.

Evidence for Antipyresis (Fever Reduction)

Research on the core component was also studied for outcomes related to systemic imbalance, specifically high body temperature. The research for antipyresis primarily consists of Meta-analyses and Comparative Studies focusing on the Metamizole component. Studies report how symptoms evolved in the observed populations, detailing the measurement of temperature variability in degrees and conducting research across diverse groups, including adult and pediatric patients.

Despite a robust evidence base for the core component, the specific properties of the triple combination for pure fever reduction are not the main focus of the large-scale antipyretic studies. Data for certain groups remain insufficient, and follow-up durations were limited to the immediate relief phase.

What is Still Uncertain About the Research for Tetralgin N

A primary uncertainty is the limited information from large, dedicated RCTs studying the specific fixed-dose combination. Furthermore, the role of the secondary ingredients in analgesic or spasmolytic research scenarios is not fully established by segregated evidence. Research does not determine whether an individual will respond similarly to the group patterns observed in the studies.

Key Studies & References

The Antipyretic Efficacy of Metamizole: A Systematic Review

Frequently Asked Questions (FAQ)

Common questions about Tetralgin N (FAQ)

Q: What is the main difference between Tetralgin N and standard painkillers?

Tetralgin N contains a combination of active ingredients, including Metamizole, Phenobarbital, and Caffeine. Regulatory information indicates its core pain-relieving component (Metamizole) has a mechanism distinct from conventional NSAIDs (e.g., ibuprofen). The inclusion of a mild barbiturate and a stimulant also differentiates the product.

Q: Is Tetralgin N considered a strong pain reliever?

The core analgesic component, Metamizole, is classified in official sources as a potent pain reliever. Its regulatory classification indicates it is reserved for the relief of moderate-to-severe pain.

Q: What kinds of pain is Tetralgin N most effective for treating?

In regions where it is available, official product information indicates the core component is used for acute severe pain, such as pain following injuries, surgeries, or abdominal cramps (colic). Similar combination drugs have been associated with the treatment of tension-type pain.

Q: What is the typical duration of Tetralgin N's effect?

Based on typical dosing schedules for similar fixed-combination products, relief is often sought every four hours, as needed. The duration of action for the combined ingredients is generally understood to last for approximately four to six hours.

Q: Can Tetralgin N be used for chronic headaches or migraines?

Official warnings note that due to the risk of dependence and misuse associated with its components, this type of product is not designated for the long-term management of chronic pain conditions. It is typically reserved for acute, short-term use.

Q: Does Tetralgin N have anti-inflammatory properties?

While the medication provides pain relief and is known for its strong fever-reducing effect, official monographs generally suggest it has weak or no significant anti-inflammatory properties when compared to conventional NSAIDs.

Q: How does the caffeine component in Tetralgin N influence its effect?

Caffeine is included as a central nervous system (CNS) stimulant. Regulatory texts note that it may help reduce excess blood flow in the head and is believed to contribute to the overall analgesic effect.

Q: Can taking Tetralgin N cause sleeplessness or anxiety?

Regulatory warnings for similar combination products indicate that adverse effects can potentially include concentration problems or difficulty sleeping. This effect is related to the stimulant component (Caffeine), despite the sedative component (Phenobarbital).

Q: What are the long-term risks associated with using Tetralgin N frequently?

Frequent or prolonged use is strongly discouraged due to the risk of tolerance and dependence associated with the Phenobarbital component. The Metamizole component is also associated with a rare but serious blood disorder (agranulocytosis), which is a risk noted in official regulatory materials.

Q: Can Tetralgin N interact with common cold or flu medications?

Official warnings exist about taking this medication with other Central Nervous System (CNS) depressants. Many common cold and flu products contain ingredients that fall into this category, which can increase the risk of profound sedation or dangerous respiratory depression.

Q: What foods or drinks should I avoid while taking Tetralgin N?

Official warnings advise against consuming alcohol while using this medication. Combining Tetralgin N with alcohol significantly increases the depressant effects on the central nervous system.

Q: Can teenagers safely use Tetralgin N for pain relief?

According to official prescribing information, the use of Tetralgin N is generally permitted for adolescents who are 15 years of age and older for the product’s standard labeled conditions. It is not recommended for children younger than 15 years.

Q: Can Tetralgin N be crushed or split if swallowing a whole tablet is difficult?

Official administration instructions indicate that tablets should be swallowed whole. The dose should not be crushed or chewed unless specifically authorized by a healthcare professional.

Q: Is it better to take Tetralgin N with food or on an empty stomach?

Official administration instructions for the core component, Metamizole, indicate that the oral forms can generally be taken with food or immediately after a meal. Always follow the precise instructions given by your healthcare provider for the specific product you are using.

Q: Do people report feeling 'wired' or overly energized because of the caffeine in Tetralgin N?

The caffeine component acts as a CNS stimulant. Adverse reactions for similar combinations have been reported to include an altered mental status, such as feeling dizzy or overly stimulated, which relates to the stimulant effect.

Q: Is Tetralgin N primarily used outside of the United States?

The core component, Metamizole, is banned or highly restricted in the United States and several other Western countries. However, official information shows that it remains widely available and used in many regions globally, including parts of Europe, Asia, and Latin America.

Q: Does the effectiveness of Tetralgin N decrease over time with regular use?

The Phenobarbital component is noted to be habit forming, and tolerance may occur with continued use. Tolerance refers to the body's decreased response to a drug's effect, including its pain-relieving capacity, over a period of time.

Q: What is the half-life of Tetralgin N in the body?

The medication is a combination of ingredients, each with a different half-life (the time it takes for half of the drug to be eliminated). The Phenobarbital component, for example, has a notably long elimination half-life, often lasting several days in the body.

Q: Is there a recommended way to gradually stop taking Tetralgin N after long-term use?

Official warnings indicate that the medication should not be abruptly discontinued if taken regularly. The dose should be gradually tapered (reduced slowly) by a healthcare professional to prevent the possibility of withdrawal symptoms.

Q: Are there specific symptoms that mean I should stop taking Tetralgin N immediately?

Regulatory documents outline specific symptoms associated with serious conditions, such as agranulocytosis. These symptoms, including fever, chills, sore throat, or painful mucosal changes, should be immediately reported to a healthcare professional.

How should Tetralgin N be stored and disposed of?

The official storage and disposal requirements for Tetralgin N are defined by government regulatory documents to maintain its stability and prevent misuse.

Official Storage Conditions

The medicine must be stored at a temperature not exceeding 25°C (77°F), and it must be protected from light and moisture. Do not refrigerate or freeze the tablets. It is required to keep the product in the original, tightly closed package to maintain these environmental constraints.

Child Safety and Disposal

Tetralgin N must be kept out of the sight and reach of children due to the risk of accidental ingestion. Disposal of unused or expired product must be done according to local pharmaceutical waste requirements; the product must not be thrown into wastewater or regular household trash.

Tetralgin N